Can a drug calm heart inflammation in people with TET2 mutations?

NCT ID NCT06691217

Recruiting now Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether canakinumab, an anti-inflammatory drug, can reduce blood vessel inflammation in people with coronary artery disease. Some participants have a genetic change called TET2 clonal hematopoiesis, which may increase inflammation. 120 adults will receive either canakinumab or a placebo every 3 months for a year, and researchers will measure changes in artery inflammation using CT scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: canakinumab (Ilaris)
What this could lead to: If successful, this could point toward a targeted treatment to reduce heart inflammation in people with certain genetic mutations.
What could go wrong: This is a small Phase 2 trial, so results may not confirm benefit. The drug can increase infection risk, and the effect on heart attacks is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASCVD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerotic cardiovascular disease coronary artery disorder vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASCVD ASCVD MANAGEMENT VASCULAR INFLAMMATION

Contacts and locations

Locations

Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.